Long-acting second-generation antipsychotics, beyond efficacy: a 12-month prospective study on patients' attitudes towards treatment

被引：0
|
作者：
Pietrini, F. [1 ]
Spadafora, M. [1 ]
Talamba, G. A. [1 ]
Godini, L. [1 ]
Santangelo, A. [1 ]
Chiarello, F. [1 ]
Ballerini, A. [1 ]
机构：
[1] Univ Florence, Dept Neurosci Psychol Drug Res & Child Hlth, Sect Neurosci, Florence, Italy
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2014年 / 24卷
关键词：
SCHIZOPHRENIA;
D O I：
10.1016/S0924-977X(14)70918-6
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.3.f.013
引用
收藏
页码：S573 / S574
页数：2
相关论文
共 50 条
  • [1] Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic
    Fleischhacker, WW
    Eerdekens, M
    Karcher, K
    Remington, G
    Llorca, PM
    Chrzanowski, W
    Martin, S
    Gefvert, O
    JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (10) : 1250 - 1257
  • [2] New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia
    Citrome, Leslie
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (07) : 767 - 783
  • [3] Practical guidelines for the use of long-acting injectable second-generation antipsychotics
    Jarema, Marek
    Wichniak, Adam
    Dudek, Dominika
    Samochowiec, Jerzy
    Bienkowski, Przemyslaw
    Rybakowski, Janusz
    PSYCHIATRIA POLSKA, 2015, 49 (02) : 225 - 241
  • [4] Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study
    Magliocco, Fabio
    de Filippis, Renato
    Aloi, Matteo
    Staltari, Filippo Antonio
    Gaetano, Raffaele
    Segura-Garcia, Cristina
    De Fazio, Pasquale
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2020, 24 (02) : 201 - 207
  • [5] Long-acting second-generation injectable antipsychotics for the maintenance treatment of bipolar disorder: a narrative review
    Belge, Jean-Baptiste
    Sabbe, Bernard G. C. C.
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (03) : 295 - 299
  • [6] LONG-ACTING SECOND-GENERATION ANTIPSYCHOTICS: IMPROVING SUBJECTIVE EXPERIENCE OF PHARMACOLOGICAL TREATMENT AND QUALITY OF LIFE
    Godini, L.
    Talamba, G. A.
    Lelli, L.
    Pietrini, F.
    Arcabasso, S.
    Spadafora, M.
    Lo Sauro, C.
    Ballerini, A.
    EUROPEAN PSYCHIATRY, 2014, 29
  • [7] Longitudinal changes in antipsychotic dose in patients treated with long-acting injectable second-generation antipsychotics
    Nakajima, Nozomi
    Mizoe, Nao
    Misawa, Fuminari
    Yamashita, Toru
    So, Ryuhei
    Kitagawa, Kohei
    Tanimoto, Kenichi
    Kishi, Yoshiki
    Fujii, Yasuo
    Takeuchi, Hiroyoshi
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2021, 36 (02) : 84 - 88
  • [8] Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents
    Jann, Michael W.
    Penzak, Scott R.
    CNS DRUGS, 2018, 32 (03) : 241 - 257
  • [9] The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values
    Lee, Lik Hang N.
    Choi, Charles
    Collier, Abby C.
    Barr, Alasdair M.
    Honer, William G.
    Procyshyn, Ric M.
    CNS DRUGS, 2015, 29 (12) : 975 - 983
  • [10] Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents
    Michael W. Jann
    Scott R. Penzak
    CNS Drugs, 2018, 32 : 241 - 257
12345